Item 8.01 Other Events

On February 28, 2022, CorMedix Inc. (the "Company") issued a press release announcing that it had resubmitted the New Drug Application for DefenCath to address the Complete Response Letter issued by the U.S. Food and Drug Administration a year ago. In addition, on February 28, 2022, the Company updated its corporate presentation for use in meetings with investors.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the Company's corporate presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits



Exhibit No.   Description
99.1            Press Release dated February 28, 2022
99.2            Corporate Presentation dated February 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses